Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Cerny

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Plos One|June 26, 2008
A vaccine against nicotine for smoking cessation: a randomized controlled trialJacques Cornuz, Susanne Zwahlen, Walter Felix Jungi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2004
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio Cogliatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98Giovanni Martinelli, Shu-Fang Hsu Schmitz, Urs Utiger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabineAntonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
British Journal of Haematology|January 14, 2004
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer ResearchFrancesco Bertoni, Annarita Conconi, Sergio B Cogliatti, et al.
European Urology Open Science|May 15, 2023
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice ExperimentDominik Menges, Michela C Piatti, Aurelius Omlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2011
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancerIgor Cima, Ralph Schiess, Peter Wild, et al.
Blood|February 21, 2004
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 scheduleMichele Ghielmini, Shu-Fang Hsu Schmitz, Sergio B Cogliatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trialDaniel C Betticher, Shu-Fang Hsu Schmitz, Martin Tötsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Plos One|June 26, 2008
A vaccine against nicotine for smoking cessation: a randomized controlled trialJacques Cornuz, Susanne Zwahlen, Walter Felix Jungi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2004
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio Cogliatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98Giovanni Martinelli, Shu-Fang Hsu Schmitz, Urs Utiger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabineAntonella Perotti, Alberta Locatelli, Cristiana Sessa, et al.
British Journal of Haematology|January 14, 2004
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer ResearchFrancesco Bertoni, Annarita Conconi, Sergio B Cogliatti, et al.
European Urology Open Science|May 15, 2023
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice ExperimentDominik Menges, Michela C Piatti, Aurelius Omlin, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2011
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancerIgor Cima, Ralph Schiess, Peter Wild, et al.
Blood|February 21, 2004
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 scheduleMichele Ghielmini, Shu-Fang Hsu Schmitz, Sergio B Cogliatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trialDaniel C Betticher, Shu-Fang Hsu Schmitz, Martin Tötsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Pageof 8